Nuvectis Pharma, Inc.
NVCT
$6.46
$0.6511.19%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.68% | -43.04% | -27.84% | 5.65% | 29.38% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.71% | 37.16% | 5.56% | -6.48% | 2.29% |
| Change in Net Operating Assets | 156.10% | 746.58% | 85.84% | 70.23% | -60.77% |
| Cash from Operations | -86.94% | -11.49% | 4.22% | 35.97% | 25.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 799.14% | -64.45% | 246.42% | 338.73% | 32.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -714.00% | -478.18% | -745.10% | -875.00% | 88.56% |
| Cash from Financing | 802.06% | -82.30% | 230.17% | 317.56% | 107.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,013.31% | -127.82% | 3,252.37% | 146.51% | 62.73% |